A citation-based method for searching scientific literature

Gary Kohanbash, Diego A Carrera, Shruti Shrivastav, Brian J Ahn, Naznin Jahan, Tali Mazor, Zinal S Chheda, Kira M Downey, Payal B Watchmaker, Casey Beppler, Rolf Warta, Nduka A Amankulor, Christel Herold-Mende, Joseph F Costello, Hideho Okada. J Clin Invest 2017
Times Cited: 158



Michele Ceccarelli, Floris P Barthel, Tathiane M Malta, Thais S Sabedot, Sofie R Salama, Bradley A Murray, Olena Morozova, Yulia Newton, Amie Radenbaugh, Stefano M Pagnotta, Samreen Anjum, Jiguang Wang, Ganiraju Manyam, Pietro Zoppoli, Shiyun Ling, Arjun A Rao, Mia Grifford, Andrew D Cherniack, Hailei Zhang, Laila Poisson, Carlos Gilberto Carlotti, Daniela Pretti da Cunha Tirapelli, Arvind Rao, Tom Mikkelsen, Ching C Lau, W K Alfred Yung, Raul Rabadan, Jason Huse, Daniel J Brat, Norman L Lehman, Jill S Barnholtz-Sloan, Siyuan Zheng, Kenneth Hess, Ganesh Rao, Matthew Meyerson, Rameen Beroukhim, Lee Cooper, Rehan Akbani, Margaret Wrensch, David Haussler, Kenneth D Aldape, Peter W Laird, David H Gutmann, Houtan Noushmehr, Antonio Iavarone, Roel G W Verhaak. Cell 2016
Times Cited: 942




List of shared articles



Times cited


Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Padma Kadiyala, Stephen V Carney, Jessica C Gauss, Maria B Garcia-Fabiani, Santiago Haase, Mahmoud S Alghamri, Felipe J Núñez, Yayuan Liu, Minzhi Yu, Ayman Taher,[...]. J Clin Invest 2021
9

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Ilaria Maggio, Raffaele Lodi, Alba Ariela Brandes. Mol Diagn Ther 2021
1

The implications of IDH mutations for cancer development and therapy.
Christopher J Pirozzi, Hai Yan. Nat Rev Clin Oncol 2021
1

Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.
Maria B Garcia-Fabiani, Santiago Haase, Andrea Comba, Stephen Carney, Brandon McClellan, Kaushik Banerjee, Mahmoud S Alghamri, Faisal Syed, Padma Kadiyala, Felipe J Nunez,[...]. Front Oncol 2021
0

Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies.
Ana Rita Pombo Antunes, Isabelle Scheyltjens, Johnny Duerinck, Bart Neyns, Kiavash Movahedi, Jo A Van Ginderachter. Elife 2020
47

Radiomic profiles in diffuse glioma reveal distinct subtypes with prognostic value.
Peng Lin, Yu-Ting Peng, Rui-Zhi Gao, Yan Wei, Xiao-Jiao Li, Su-Ning Huang, Ye-Ying Fang, Zhu-Xin Wei, Zhi-Guang Huang, Hong Yang,[...]. J Cancer Res Clin Oncol 2020
3

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.
Sue Han, Yang Liu, Sabrina J Cai, Mingyu Qian, Jianyi Ding, Mioara Larion, Mark R Gilbert, Chunzhang Yang. Br J Cancer 2020
50

Cellular Plasticity and Tumor Microenvironment in Gliomas: The Struggle to Hit a Moving Target.
Ricardo Gargini, Berta Segura-Collar, Pilar Sánchez-Gómez. Cancers (Basel) 2020
5

A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.
Jie Xu, Fang Liu, Yuntao Li, Liang Shen. Cell Mol Neurobiol 2020
2

New hints towards a precision medicine strategy for IDH wild-type glioblastoma.
K White, K Connor, J Clerkin, B M Murphy, M Salvucci, A C O'Farrell, M Rehm, D O'Brien, J H M Prehn, S P Niclou,[...]. Ann Oncol 2020
7

Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma.
Eliana Marinari, Mathilde Allard, Robin Gustave, Valérie Widmer, Géraldine Philippin, Doron Merkler, Petros Tsantoulis, Valérie Dutoit, Pierre-Yves Dietrich. Oncoimmunology 2020
7

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins.
Bozena Kaminska, Bartosz Czapski, Rafal Guzik, Sylwia Katarzyna Król, Bartlomiej Gielniewski. Molecules 2019
31